Bell Potter Healthcare Conference Presentation
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Bell Potter Healthcare Conference Presentation
19 November 2026 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon”
or “the Company”), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for
neurodegenerative diseases, is pleased to provide the attached presentation to be delivered by Chief Executive
Officer, Dr Chris Bremer, at the Bell Potter Healthcare Conference on Thursday, 19 November 2026.
The conference, being held virtually from 17 to 19 November 2026, brings together leading ASX-listed healthcare
companies to share business updates, growth strategies and upcoming milestones with the investment community.
The presentation provides an overview of Neurizon’s clinical development program for NUZ-001, including progress
in the Phase 2/3 HEALEY ALS Platform Trial, recent regulatory and operational developments, the Company’s funding
position and key milestones ahead of the anticipated topline results in late Q2 CY2027.
The presentation is attached to this announcement.
-ENDS-
This announcement has been authorised for release by Dr Chris Bremer, Chief Executive Officer, on behalf of the
Board of Neurizon Therapeutics Limited.
For further information, please contact:
Marketing & Corporate Affairs
Lidija Damjanovic
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504
Investor Relations
Henry Jordan
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader
neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is
dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an
investigational product and is not approved for commercial use in any jurisdiction.
Neurizon Investor Hub
We encourage you to utilise our Investor Hub for any enquiries regarding this
announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view
video summaries of key announcements.
To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com
Neurizon® is a registered trademark of Neurizon Therapeutics Limited
ABN 35 094 006 023
Advancing an oral ALS therapy
toward a defining clinical readout
Bell Potter Healthcare Conference – 19 November 2026
Dr Chris Bremer, Chief Executive Officer
2
Disclaimer
This presentation has been prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”). This
disclaimer applies to the presentation and all information contained in it. It does not purport to contain
all the information that a prospective investor may require in connection with any potential investment in
the Company. You should not treat the contents of this presentation, or any information provided in
connection with it, as financial advice, financial product advice or advice relating to legal, taxation or
investment matters.
No representation or warranty (whether express or implied) is made by the Company or
any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of
the information, statements, opinions or matters (express or implied) arising out of, contained in or
derived from this presentation or provided in connection with it, or any omission from this presentation,
nor as to the attainability of any estimates, forecasts or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own independent inquiries
into the matters contained in the presentation and make your own independent decisions about the
affairs, financial position or prospects of the Company.
The Company reserves the right to update, amend or supplement the information at any time in its
absolute discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees
accept any responsibility or liability to you or to any other person or entity arising out of this presentation
including pursuant to the general law (whether for negligence, under statute or otherwise), or under the
Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and
Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the
law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any
such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and
excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or
sell securities. It does not include all available information and should not be used in isolation as a basis to
invest in the Company.
Future Matters
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects
of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be
achieved. They are based on certain assumptions, which may not be met or on which views may differ and
may be affected by known and unknown risks. The performance and operations of the Company may be
influenced by a number of factors, many of which are outside the control of the Company. No
representation or warranty, express or implied, is made by the Company, or any of its directors, officers,
employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or
partially or that any particular rate of return will be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or
achievements to be materially different from those expected, planned or intended, recipients should not
place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company
does not warrant or represent that the actual results, performance or achievements will be as expected,
planned or intended.
US Disclosure
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any
securities in the United States or to, or for the account or benefit of any “US person” as defined in
Regulation S under the US Securities Act of 1933 (“Securities Act”). The Company’s shares have not been,
and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of
the United States, and may not be offered or sold in the United States or to any US person without being so
registered or pursuant to an exemption from registration including an exemption for qualified institutional
buyers.
Investor Webinar - November 2026
Our Vision
To lead the development of treatments
towards a promising new horizon for
people living with neurodegenerative
diseases.
Why look now
4
A randomised Phase 2/3 readout in late Q2 2027 is the next value inflection
Late Q2 2027
Expected topline from the 250-
participant Phase 2/3 ALS trial.
Clinical advancement
A 250-participant randomised Phase 2/3 enrolled
in less than 5 months – record enrolment for the
HEALEY ALS Platform Trial.
NIH-funded EAP for NUZ-001.
Evidence-led development and
regulatory progress
Promising Phase 1 signals, with an exploratory
biomarker panel built into ongoing Phase 2/3 trial.
Supply chain readiness for scale
Long-term supply agreement with Elanco
for GMP API supply and registration-scale
manufacturing.
Strategic and commercial optionality
An upcoming, randomised Phase 2/3 dataset that
will inform Neurizon’s regulatory, partnering and
commercial strategy.
1
3
2
4
NIH-Funded EAP
for NUZ-001 for 200 participants
up to 96 weeks.
1 Illustrative US TAM of approximately US$5 billion based on projected 2026 US ALS prevalence of approximately 34,720 adults (CDC National ALS Registry) and assumed
annual net pricing of US$150,000 per patient.
Funding secured
Fully funded through to HEALEY
topline results. Outstanding
convertible notes redeemed.
Bell Potter Healthcare Conference - November 2026
FDA Type C feedback indicated that positive
HEALEY results could potentially support a
traditional US approval pathway for NUZ-001.
Total addressable market (TAM) opportunity of
~US$5bn1.
ALS contributes to progressive degeneration of motor neurons, leading to
increasing loss of voluntary muscle function
ALS AT A GLANCE
2–5 YEARS
Typical life expectancy following
diagnosis*
~90%
of ALS cases are without family history
NO CURE
Significant unmet
medical need remains
~35,000
people living with ALS in the US1
No approved therapy has substantially altered the course of ALS progression
for the broad patient population.
A therapy that slows ALS meaningfully, in a broad population, with oral
dosing, would address a substantial need in the ALS/MND market.
*Disease course varies considerably between individuals. Sources for final deck: ALS Association / peer-reviewed literature; verify wording and citations before publication.
.1. US prevalence estimate as used in company materials.
SPEECH
Loss of ability
to speak
SWALLOWING
Increasing
difficulty
swallowing
MOVEMENT
Progressive loss
of muscle
function
BREATHNG
Increasing
difficulty
breathing
ALS is a rapidly progressive neurodegenerative disease with significant
unmet need
5
Bell Potter Healthcare Conference - November 2026
6
FUS = Fused in Sarcoma; SOD1 = Superoxide Dismustase 1; TDP-43 = Transactive response DNA-binding protein 43
1. Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein
homeostasis. Neuron. 2013 Aug 7;79(3):416-38. doi: 10.1016/j.neuron.2013.07.033.
In most ALS/MND, nuclear TDP-43 is lost and accumulates in the cytoplasm, disrupting RNA processing, axonal
maintenance and communication with muscles
TDP-43 dysfunction & aggregation links ALS pathology to motor neuron
failure
Bell Potter Healthcare Conference - November 2026
1 2 3
<1%
FUS Mutation
~2%
SOD1 Mutation
97%
TDP-43 Aggregation
A SHARED PATHOLOGY
of ALS cases
show
TDP-43
pathology1
TDP-43 IS LOST FROM THE NUCLEUS AND
BUILDS UP IN THE CELL
Nuclear TDP-43 Loss
Cellular TDP-43 Aggregation
The neuron loses normal function
while harmful protein burden increases.
THE MOTOR NEURON–MUSCLE
CONNECTION BREAKS DOWN
A
B
C
Impaired axon maintenance and
synaptic vesicle release unreliable
muscle control
Cytoplasmic toxic aggregates trap
essential proteins impair axon
transport
Cytoplasmic aggregates stress
cellular machinery starve
motor neurons
NUZ-001 shown in preclinical studies to
enhance cellular protein clearance
mechanisms to support motor neuron
proteostasis
A
B C
Pre-clinical Evidence Supporting NUZ-001 Potential in ALS/MND
7
Prevents cellular TDP-
43 aggregation
Enhances protein clearance
mechanisms (autophagy &
proteosomal system)
Preserves STMN2
expression to support
neuronal health
Restores NfL axonal health
and synaptic signalling
+ NUZ-001
NfL = Neurofilament Light, STMN2 = Stathmin-2; TDP-43 = Transactive response
DNA-binding protein 43
Consistent effects observed
across models:
MND-patient
motor neurons
Zebrafish
Human
neurospheres
NUZ-001 Enhances Protein Clearance Pathways to Remove Toxic Protein Aggregates
Bell Potter Healthcare Conference - November 2026
-2.93 -1.65
-5
-4.5
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
PRO-ACT Matched Controls
(n=420) NUZ-001 (n=12)
-1.21 -0.83
-2
-1.8
-1.6
-1.4
-1.2
-1
-0.8
-0.6
-0.4
-0.2
0
PRO-ACT Matched Controls
(n=360) NUZ-001 (n=12)
ALSFRS-R
Slope
(points/month)
Phase 1b & Open Label Extension Results
Preliminary Signals of Efficacy in ALSFRS-R and SVC
8
Treatment with NUZ-001 across combined Phase 1 and OLE studies slowed the progression of ALS in all patients by 31% for ALSFRS-R and 43% for SVC
percent predicted (PP) when compared to matched controls from the PRO-ACT historical database1
1. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses, and predictive features.
Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834
2. Forced vital capacity (FVC) was used when SVC was not collected
3. Matched on time since onset, baseline ALSFRS-R, pre-baseline slope, and disease onset location
Motor Function – ALSFRS-R
Difference
0.37 points/month (p=0.145)
Difference
1.27 points/month (p=0.078)
31% 43%
Respiration – SVC PP2
3 3
VC
PP
Slope
(points/month)
Bell Potter Healthcare Conference - November 2026
Phase 1b & Open Label Extension
NUZ-001 shows improved survival vs matched controls
9
NUZ-001 treatment resulted in statistically
significantly longer survival of participants with ALS,
(X2=11.35, p=0.00075), compared to matched
controls1 from the PRO-ACT database2
1. Matched on time since onset, baseline ALSFRS-R, pre-baseline ALSFRS-R slope, and disease onset location
2. Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, Walker J, Katsovskiy I, Schoenfeld D, Cudkowicz M, Leitner M. The PRO-ACT database: design, initial analyses,
and predictive features. Neurology. 2014 Nov 4;83(19):1719-25. doi: 10.1212/WNL.0000000000000951.Epub 2014 Oct 8. PMID: 25298304; PMCID: PMC4239834
Analysis* suggests that treatment with NUZ-001 reduces
the risk of death by 71%:
Hazard ratio of 0.29 (95% CI: (0.131, 0.644), p = 0.0024)
Bell Potter Healthcare Conference - November 2026
* Neurizon Phase 1 and Open Label Extension Study data from September 2025
Regimen I is designed to investigate clinical benefit
10
REGIMEN I AT A GLANCE
Design Double-blind, placebo-controlled adaptive Phase 2/3 under the HEALEY master protocol
Participants 250 enrolled at close of recruitment (protocol expanded from 160 to 240 in May 2026)
Randomisation 3:1 NUZ-001 to placebo — a fully concurrent, internally consistent placebo arm
Dose and route 10 mg/kg once daily, oral — the dose carried forward from the Phase 1b open-label extension
Treatment period 36-week double-blind period, followed by a 36-week active treatment extension
36-week blinded period
Earlier HEALEY regimens read out at 24 weeks. A longer
blinded window gives more time for functional curves
to separate in a disease where treatment effects
accumulate slowly and variably, and optimises the
chance of showing a clinically meaningful treatment
effect.
Fully concurrent placebo arm
Regimen I carries its own placebo group, removing the
temporal-drift and comparability associated with pooled
placebos.
Primary and Secondary Endpoints
WHY THESE DESIGN CHOICES MATTER
Recruitment complete
July CY2026
All participants enrolled
and dosing commenced
RCT Completion
Early Q2 CY2027
36-week randomised
period, then active
extension
Database lock
Q2 CY2027
Data cleaning and validation
Topline result
Late Q2 CY2027
Primary efficacy and safety
readout
P: Change in ALSFRS-R and survival from baseline to Week 36
S: Slow vital capacity from baseline to Week 36
S: Freedom from death or permanent assisted ventilation from
baseline to Week 36
Bell Potter Healthcare Conference - November 2026
Exploratory Endpoints
Biological validation of disease progression and mechanism of
action through extensive exploratory biomarker panel (NfL,
mtDNA, protein panel, speech)
Cost and Capital Management
A simplified capital structure, fully funded1 structure to HEALEY topline in Q2 CY2027
No convertible notes on issue. Capital efficient program. Material non-dilutive funding. Near term readout
SIMPLIFIED FUNDING STRUCTURE
• Outstanding Obsidian convertible notes redeemed,
reducing overhang and selling pressure.
• Facility remains in place but will only be drawn if in
shareholders’ interests - after assessing other funding
opportunities.
• Strong SPP participation may remove the need for any
further drawdown.
DISCIPLINED CAPITAL ALLOCATION
Focused Spend prioritised to HEALEY topline;
all other costs reduced. Regimen I
expanded with no funding impact.
~30% Lower research cost via HEALEY’s
shared sites and infrastructure1
Elanco Capital efficient regulatory and
manufacturing readiness through
Elanco License and Supply Agreements
NON-DILUTIVE FUNDING
• R&D Tax Incentive: Advance and Overseas Finding
supports substantial rebate on R&D spend (including
HEALEY). Funding accelerated to reduce dilution via
the Dare Capital Strategic R&D loan.
• Expanded Access Program: EAP for up to 200
participants – fully funded by US NIH.
• HEALEY / MGH: Philanthropic contribution towards
the cost of expanding Regimen I from 160 to 250
participants.
RECENT PLACEMENT
$4.3m Funds raised at 6.8c from new and
existing institutional, sophisticated
and professional investors.
SHARE PURCHASE PLAN
Target $2m Up to $30,000 per holder at 6.8c,
plus one free option per share (12c,
18 months; subject to shareholder
approval).
CONVERTIBLE NOTES ON ISSUE
Zero All remaining Obsidian notes redeemed
and resolution to support drawdown
after 2026 AGM withdrawn.
1. Funding strategy to topline readout includes one further facility drawdown (not before April 2027 and subject to shareholder approval), with the ability to displace it with alternative
funding. Multiple alternative funding avenues are under development and assessment.
2. https://wfneurology.org/activities/news-events/archived-news/2023-10-17-wcn-cudkowicz
11
Bell Potter Healthcare Conference - November 2026
ALS: high unmet need with significant value potential
12
Three decades of approvals have delivered limited clinical benefit
Key ALS Value Reference Point:
Shionogi – RADICAVA (2026)
US$2.5B
Upfront for global rights paid by Shionogi to Tanabe
Pharma
~US$700M
Expected annual global sales
• Commercial, revenue-generating ALS franchise
• Oral product US patent until 2039
• Rare disease commercial platform foundation
Current US ALS treatment landscape
2017 IV
2022 ORAL
RILUZOLE
Broad ALS population | Oral
RADICAVA® / RADICAVA ORS®
Broad ALS population | IV & oral
QALSODY®
SOD1-ALS only | Intrathecal
1995 2023
~3 months
median survival extension
across randomized
controlled trials
~6 months
median survival extension
across randomized
controlled trials
~3 years
median survival extension
in pivotal VALOR trial
Protects neurons from
overactivation-induced
death
Reduces neuron
degeneration as antioxidant
in the nervous system
Binds to mRNA of SOD1 to
prevent toxic protein cluster
formation in neurons
1 2 3
4
1. Hinchcliffe et al. 2017, Degenerative Neurological and Neuromuscular Disease 7 (May): 61–70.
2. Takahashi et al. 2025, Muscle & Nerve 72 (4): 586–96.
3. Miller et al. 2026 JAMA Neurology 83 (2): 115–25.
4. Shionogi press release, 22 December 2025; transaction completion announced April 2026
Bell Potter Healthcare Conference - November 2026
A roadmap to topline readout and beyond
Multiple material developments converging over the coming quarters
Q4 CY2026
Expanding Pre-Clinical
Evidence
Addressing MOA questions
CY2027
Expanded Access
opens
Adds long-term safety and
real-world data in a
broader population
Q2 CY2027
Trial completion and
database lock
Final step before
unblinding
Late Q2 CY2027
HEALEY topline
First randomised efficacy
data: the defining event
Post-topline
Regulatory
engagement on the
data
Potentially registrational
trial
Timing reflects current company guidance and planning, and may change. EMA advice and Expanded Access timing to be confirmed by management before external use. 13
Bell Potter Healthcare Conference - November 2026
Investment summary
14
A defining randomised readout in late Q2 CY2027, with groundwork in place
Late Q2
CY2027
HEALEY Regimen I topline: the
first randomised efficacy data
for NUZ-001.
1 A 250-participant randomised Phase 2/3 in ALS, efficiently run
2 Record enrolment within the HEALEY platform, in under five months
3 Early clinical signals that shaped the Phase 2/3 trial design
4 Supply, manufacturing and biomarker work already in place
5
Established regulatory foundations with partnering and commercial
optionality
Bell Potter Healthcare Conference - November 2026
Registered Address:
Suite 2, Level 11, 385 Bourke Street
Melbourne, VIC 3000 Australia
+61 (3) 9692 7222
enquiries@neurizon.com
Thank You
Share your feedback
Discover